All Eli Lilly articles
-
BusinessWeight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments
-
ResearchInsulin medicines more resilient to temperature than previously thought
Review suggests more lenient storage guidelines could make diabetes treatments more accessible
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
BusinessThe diabetes drugs aiming to aid weight loss
Can peptide hormone mimics avoid the side effect pitfalls of previous weight loss treatments?
-
BusinessCoronavirus variants stymie success of monoclonal antibodies
Lab-made antibodies can treat and protect people from Covid-19 but are more likely to succeed when administered as a cocktail
-
NewsWhy jury verdicts get overruled in US industry cancer trials
Judges often end up intervening post-trial in complex cases with conflicting scientific evidence
-
BusinessLandmark China cancer drug full approval ‘first of a wave’
Chi-Med’s fruquintinib is a result of China’s evolving drug innovation and regulation
-
BusinessLilly and CureVac to collaborate on mRNA cancer vaccines
Deal could see CureVac net up to $1.8 billion in upfront and milestone payments
-
OpinionRise of the biologics
Antibodies, RNA and gene therapy don’t necessarily compete with small molecule drugs – and they all rely on chemistry
-
BusinessEli Lilly to cut 3500 jobs
Company will close sites in US and China, and provide incentives for early retirement
-
BusinessLilly wins chemotherapy patent appeal
Firm also settles with generic manufacturers of erectile dysfunction drug Cialis
-
ResearchLilly pushes continuous drug production limits
Integrated flow synthesis and purification process for prexasertib meets high industry standards
-
FeatureCovalent inhibitor drugs
Exceptions to a long-held rule against chemically bonding to biological targets are powering new cancer medicines, finds Andy Extance
-
BusinessLilly loses arbitration over Canadian patents
Firm had sought recompense under the Nafta trade agreement
-
NewsAlzheimer’s disease: have drug developers been on the wrong track?
Dementia drug developers urged to look beyond amyloid
-
BusinessLilly buys CoLucid for migraine drugs
US firm also laying off 485 sales staff after Alzheimer’s drug failure
-
BusinessLilly to buy Boehringer’s pet vaccines
Deal strengthens Lilly’s animal medicine division following recent acquisition
-
BusinessNovo Nordisk to axe 1000 jobs
Diabetes specialist is cutting costs in the face of increased competition
-
Business
Lilly loses UK patent challenge
Allergan’s cancer drug generics do not infringe patents, say UK courts
-
